The real PSMF problem has little to do with templates, version control, or how fast a document can be assembled. It is a problem of time: the lag between something changing in the pharmacovigilance system and that change appearing, accurately, in the file meant to represent it. Call it PSMF latency.
Consider what this looks like in practice. An inspector points to a single line in Annex B: a named vendor, listed as running literature screening for two markets. She asks to see evidence that the arrangement still works the way the file describes. It doesn’t. That activity moved to a different provider the previous autumn. The contract was updated. So was the SOP. The QPPV was told. The one place that never caught up was the master file annex.
No one was careless. The change travelled through the parts of the organisation that had to act on it, and never reached the part that has to describe it. By the time the inspection arrives, the Pharmacovigilance System Master File is telling a story about a system that has quietly moved on.
A system that never holds still
A pharmacovigilance system changes constantly, and rarely on a schedule anyone owns. A product is authorised in a new territory. A vendor is swapped. An SOP is retired and replaced. A local contact person leaves. Medical review is centralised into a regional hub. A signal-detection step is adjusted after an audit finding. An AI tool is introduced to triage incoming cases.
Every one of these has a plausible knock-on effect for the master file. But the signal that “something changed” can be buried in a contract amendment, a set of meeting minutes, a quality record, an email thread, an affiliate’s spreadsheet. The owner is left to reconstruct the current state of the system from fragments.
Latency is the space between the change and its reflection. In a small, stable, single-market operation, that space was tolerable. In a global organisation running multiple marketing authorisations, dozens of vendors, hybrid local-and-global models and a growing layer of automation, it has become the place where compliance risk quietly accumulates.
The scale of the coordination problem is easy to underestimate. A midsize MAH managing 300 generic products may have more than twenty functions and individuals with a stake in the accuracy of the master file — medical affairs, pharmacovigilance operations, regulatory affairs, legal, procurement, local affiliates, IT, contracted service providers. None of them owns the PSMF. Each of them owns a piece of the system it describes.
The standard response to this has been to distribute the update burden: give each function access to their section, agree an annual review cycle, announce dates at the start of the year, hold a kick-off meeting, set deadlines. In practice, this creates a different problem. Shared access without coordination produces duplication and inconsistency. And the annual cycle, even when it runs perfectly, only captures changes that happened to be scheduled. The vendor switch that happened in October, the SOP revised in February, the role that changed hands without a formal handover — these sit outside the cycle. By the time the annual review arrives, the file is already behind.
This is the structural source of latency. It is not a process that needs to be run better. It is a process that was designed for a static system being applied to one that moves continuously.
Regulators are already measuring the symptom
This shows up in the inspection record, not just in anecdote.
At its 2024 GPvP Symposium, the MHRA confirmed that between 2016 and 2023, the same three areas — Risk Management, Ongoing Safety Evaluation, and the Quality Management System — have consistently topped the findings table. This is not a recent anomaly. It is a seven-year pattern.
These are not freak failures. They are the predictable residue of systems that change faster than their documentation can absorb — and a PSMF that is updated reactively, after the fact, will always be chasing that gap.
Within the master file itself, the weak point is consistent: the annexes. The main body describes how pharmacovigilance is meant to work. The annexes are where that description meets operational reality, and where it most often fails to hold. When the agency has set out where PSMF findings concentrate, the lists do most of the damage, the inventory of contracts and delegated activities and the list of products the system actually covers. Those are precisely the parts of the file that depend on information owned by other functions, held in other systems, updated on other clocks. The MHRA has also been explicit that it expects oversight of partners to be backed by real evidence rather than a returned questionnaire. A master file written as confident narrative, with nothing underneath it, is becoming a liability.
Borrowing a fix from software
Pharmacovigilance is not the first discipline to learn that a written description of a system drifts away from the system itself. Software infrastructure teams hit the same wall more than a decade ago and gave it a name: configuration drift.
The parallel translates directly. The PSMF is the declared state. The PV system is the live state. Latency is the drift between them. What is worth taking from software is not the vocabulary but the response: that field did not solve drift by writing tidier documents. It solved it by making drift visible in real time, so it could be investigated and reconciled before it became a liability.
That last shift is the one the PSMF logbook needs most. Most logbooks today are a chronology of edits: date, section, version, approver. Useful for an audit trail, thin on meaning. A reconciliation logbook records system change, not document change. The difference is between an entry that reads “Annex B updated” and one that reads “literature screening for Germany and Austria moved to a new vendor; delegated activities and SOP references revised; QPPV notified; oversight evidence on file; affected annexes and the relevant main-body description brought back into line.” Only one of those is something an inspector can actually follow.
What becomes possible with visibility
None of this requires the master file to vanish into a monolithic safety platform, and none of it is fixed by a better Word template. It asks for a change in posture.
The obstacle is rarely intent. Most of the functions that generate PSMF-relevant changes — legal, procurement, affiliates, IT — are doing their jobs. The problem is that no single person can see, at any moment, where the description of the system has drifted from the system itself. That is not a process failure a better SOP will fix. It is a visibility problem.
When the QPPV has a live view of what is current, what is contested, and what is overdue, the dynamic changes. Changes in products, vendors, SOPs, and roles surface as they happen rather than accumulating until review time. Evidence is retrieved rather than reassembled under time pressure. Local master files can inherit a governed global core and localise only what genuinely differs. And the QPPV can exercise real oversight — not an oversight model that rests entirely on people remembering to escalate.
The part AI makes urgent
AI has entered pharmacovigilance through case intake, duplicate detection, literature screening, coding and signal work, and it arrived faster than the language used to govern it. That widens the gap rather than closing it. Where an automated capability supports a regulated process, the master file will eventually need to explain where it sits, whether its output is advisory or decisive, what human oversight exists, how it is validated, and how changes to the model are controlled.
The shift worth making
For most of its life the master file has answered one question: what does the pharmacovigilance system look like? The more useful question, and the harder one, is whether that description is still true today, and whether the organisation can prove it.
Reducing PSMF latency is how a master file stops being a periodic act of reconstruction and starts to behave like a live reading of the system it represents. Companies that manage that gap well will not simply produce documents faster. They will understand their own pharmacovigilance systems better, walk into inspections with less to rebuild, give their QPPVs genuine visibility, and stand on firmer ground as automation spreads through drug safety.
This article was written by Qinecsa, a technology company building tools that give pharmacovigilance teams real-time visibility into PSMF currency and drift.
About the author
Sandeep Mahagaonkar is Vice President, Product Safety at Qinecsa. He has more than two decades of experience across engineering, product leadership, and commercial strategy in life sciences SaaS. Over the years, he has led the evolution of product portfolios across pharmacovigilance, medical affairs, and compliance, working closely with global customers to align product direction with real-world operational needs.
His work has focused on simplifying complex safety workflows and enabling organisations to operate with greater efficiency and confidence. He has played a key role in driving AI-enabled capabilities, bringing a practical and grounded approach to the adoption of automation in pharmacovigilance.